Open AccessFDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
Author(s) -
Emerson Y. Chen,
Alyson Haslam,
Vinay Prasad
Publication year - 2020
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2020.1097
Subject(s) - medicine , surrogate endpoint , cancer drugs , retrospective cohort study , cancer , drug approval , drug , medical physics , intensive care medicine , surgery , pharmacology
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom